Recent developments include clinical enrollment milestones, dosing of first subjects in key trials, financial results improvements, and trading activity updates.

• Ensysce Biosciences reported improved financial results for the fiscal year ended December 31, 2025 [N1].
• The company reached 50% enrollment milestone in its pivotal Phase 3 trial of PF614 as of January 2026 [N2].
• Ensysce narrowed its loss in Q2 2025, reflecting progress in financial management [N3].
• The company announced a partnership with a specialty drug manufacturer in December 2024 to support development efforts [N8].
• Ensysce dosed the first subjects in the PF614-MPAR trial in November 2024, advancing its overdose protection program [N9].
• Trading of Ensysce Biosciences shares was halted and resumed multiple times in December 2024 due to news pending and volatility [N5][N6][N7].

Ensysce Biosciences has developed innovative opioid prodrug platforms that address critical public health issues related to opioid abuse and overdose. Its lead candidate PF614 has demonstrated safety, bioequivalence to established opioid products, and resistance to multiple abuse routes in clinical studies. The MPAR® technology adds a novel overdose protection mechanism, with FDA Breakthrough Therapy designation highlighting its potential significance. The initiation and progress of a pivotal Phase 3 trial for PF614 and ongoing clinical trials for PF614-MPAR represent important execution milestones. Partnerships with specialty drug manufacturers and sufficient clinical supplies support development continuity. The company’s proprietary technology and intellectual property position it to potentially offer safer opioid therapies that could meet unmet medical needs.

Ensysce Biosciences is a clinical-stage company with no approved products or revenues, operating at a loss and dependent on additional financing to continue operations. The development of opioid prodrug candidates involves significant clinical, regulatory, and manufacturing risks, including the possibility of trial delays, failure to obtain regulatory approvals, or inability to scale manufacturing cost-effectively. The company relies on third-party contract manufacturers, which may pose supply risks. Competition from other companies with abuse-deterrent opioid products and emerging non-opioid pain therapies may limit market opportunities. Intellectual property protection may be challenged, and the company’s limited operating history and small workforce may constrain its ability to execute its business plan effectively.

Ensysce Biosciences’ moat is based on its proprietary molecular delivery technologies (TAAP and MPAR®) that aim to deter opioid abuse at the molecular level, differentiating from existing formulation-based abuse deterrent products. The TAAP platform’s enzyme-mediated activation localized in the gastrointestinal tract and resistance to physical manipulation provide a unique approach to abuse deterrence. The MPAR® technology adds overdose protection by inhibiting prodrug activation when taken in excess. The company’s intellectual property portfolio, including patents and trade secrets, supports protection of these technologies. Additionally, FDA Breakthrough Therapy designation for PF614-MPAR underscores regulatory recognition of the product’s potential. However, the company remains in clinical development with no commercial products, and competition exists from other firms developing abuse-deterrent opioid formulations.

• Clinical and Regulatory Risk: The company’s product candidates are in clinical development and may not demonstrate safety or efficacy sufficient for regulatory approval. Regulatory authorities may require additional studies or deny approval.
• Financial Risk: Ensysce has incurred significant losses and depends on raising additional capital to fund operations. Failure to secure financing could limit development activities and threaten business continuity.
• Manufacturing and Supply Risk: Reliance on third-party contract manufacturers introduces risks related to supply disruptions, quality control, and regulatory compliance, which could delay clinical trials or commercialization.
• Market and Competitive Risk: The opioid pain management market is competitive with existing abuse-deterrent formulations and emerging non-opioid therapies. Market acceptance of Ensysce’s products is uncertain.
• Intellectual Property Risk: Protection of proprietary technology depends on patents and trade secrets, which may be challenged or insufficient to prevent competition.

• Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing innovative solutions for severe pain relief while reducing opioid misuse, abuse, and overdose [S1].
• The company develops product candidates primarily targeting opioid pain products and opioid use disorder products [S1].
• Ensysce's proprietary technology platforms include the Trypsin Activated Abuse Protection (TAAP) platform and the Multi-Pill Abuse Resistant (MPAR®) platform [S1].
• TAAP technology is a molecular delivery system designed to release active drugs only when exposed to specific physiological conditions, notably the digestive enzyme trypsin, aiming to deter abuse by oral and non-oral routes [S1].
• PF614 is the lead TAAP prodrug candidate, a delayed-release oxycodone prodrug designed to resist oral and non-oral abuse, with clinical trials including Phase 1, Phase 1b, and a pivotal Phase 3 trial initiated in July 2025 [S1].
• PF614-MPAR is a combination product of PF614 and nafamostat (a trypsin inhibitor) designed to provide overdose protection by limiting conversion of the prodrug to active opioid when taken in excess [S1].
• PF614-MPAR received FDA Breakthrough Therapy designation in January 2024 and is undergoing clinical trials including PF614-MPAR-101 and PF614-MPAR-102 [S1].
• The company has completed multiple clinical studies demonstrating safety, pharmacokinetics, bioequivalence to OxyContin, and human abuse potential assessments for PF614 [S1].
• Ensysce's technology aims to address multiple modes of opioid abuse including oral excess ingestion, nasal snorting, injection, and poly-pharmacy [S1].
• The company relies on contract manufacturing organizations (CMOs) for production of clinical and potential commercial quantities of its product candidates and currently has sufficient supplies for clinical trials [S3].
• Ensysce has no products approved for commercial sale and has not generated revenue from product sales; it has incurred significant losses since inception and expects to continue incurring losses [S8, S11].
• As of December 31, 2025, Ensysce had cash and cash equivalents of approximately $4.31 million and current assets of about $7.24 million, with current liabilities of approximately $4.57 million, resulting in a current ratio of 1.59 and a cash ratio of 0.94 [S4].
• The company has eight full-time employees and two part-time employees, with a majority holding Ph.D. degrees [S14].
• Ensysce has announced partnerships with specialty drug manufacturers to support its development programs [N8].
• Recent news highlights include reaching 50% enrollment in the pivotal Phase 3 trial of PF614, dosing first subjects in the PF614-MPAR trial, and reporting improved financial results [N1, N2].
• The company has experienced trading halts and resumptions in late 2024 related to news pending and volatility [N5, N6, N7].
• Ensysce discloses material information through SEC filings, press releases, investor relations website, and social media channels [S1].
• The company faces risks related to its limited operating history, lack of commercial products, dependence on additional financing, and uncertainties inherent in clinical development and regulatory approval processes [S11, S18].
• Ensysce's intellectual property strategy includes patents, trade secrets, and confidentiality agreements to protect proprietary technology [S5].
• The company is subject to regulatory requirements including DEA controls for its opioid prodrug substances [S3].